Market News & Trends
G1 Therapeutics Announces Publication in Cancer Discovery
G1 Therapeutics, Inc. recently announced the publication CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation, is available online in the journal Cancer Discovery.…
Organovo & Viscient Biosciences Collaborate to Develop Custom Research Platform
Organovo Holdings, Inc. and Viscient Biosciences recently announced a collaboration to develop a custom research platform for studying liver disease. The partnership is expected to…
Citoxlab Acquires American CRO Xenometrics
Citoxlab Group recently announced the acquisition of Xenometrics, an American CRO specialized in the non-clinical assessment of new drug candidates. This acquisition is the third…
Sarepta Therapeutics Signs Exclusive Global Collaboration
Sarepta Therapeutics, Inc. recently announced it has signed a research collaboration agreement with Duke University, granting the company an option to an exclusive license to…
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. recently announced the presentation of preliminary data from an ongoing Phase 2 proof-of-concept study evaluating the safety and efficacy of setmelanotide, the…
Novoteris Investigator Receives Health Canada Clearance to Start Phase 2a Clinical Trial
Novoteris, LLC recently announced that the Therapeutic Products Directorate of Health Canada has cleared an investigator sponsored, pilot clinical trial application exploring the treatment of…
Arcturus Therapeutics & Synthetic Genomics Announce Strategic Alliance
Arcturus Therapeutics, Inc. and Synthetic Genomics, Inc. recently announced they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines…
Catalent Collaborates With Grid Therapeutics to Develop Novel Targeted Immuno-Oncology Therapy
Catalent Pharma Solutions recently announced it has signed a multi-year agreement with Grid Therapeutics, LLC, for the development and manufacture of Grid’s lead therapeutic candidate…
AC Immune SA to Receive Milestone Payment
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, recently announced that Genentech, a member…
Evonik & Eli Lilly Announce Renewal of a Long-Term Agreement
Evonik Industries and Eli Lilly and Company (Lilly) today announced the renewal of a long-term agreement under which Evonik will supply active pharmaceutical ingredients (APIs)…
Catalyst Biosciences & Mosaic Biosciences Enter Strategic Development Collaboration
Catalyst Biosciences, Inc. and privately held Mosaic Biosciences, Inc. recently announced they have entered into a strategic collaboration to develop Catalyst’s anti-C3 protease assets for…
Bracket Acquires mProve Health to Radically Advance Patient Engagement in Clinical Trials
Bracket recently announced the strategic acquisition of mProve Health Inc. (mProve), a leading provider of mobile technologies for life science companies. The acquisition centers on…
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial
Sienna Biopharmaceuticals, Inc. recently announced the first patient has been dosed in the Company’s Phase 2b clinical trial of topical product candidate SNA-120 (pegcantratinib) in…
Aclaris Therapeutics Announces the Allowance of a US Patent Application & Issuance Covering Hair Loss Disorders
Aclaris Therapeutics, Inc. recently announced that Columbia University has received a Notice of Allowance from the USPTO for a patent application covering methods of treating…
Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study
Molecular Templates, Inc. recently announced the dosing of the first patient in a Phase 1 expansion study of MT-3724, a first-generation ETB that targets the…
Cognition Therapeutics Announces Issuance of Patent for a First-in-Class Alzheimer’s Disease Clinical Candidate
Cognition Therapeutics, Inc. recently announced the USPTO has issued a composition of matter patent for a family of novel compounds including CT1812, Cognition’s first-in-class, orally…
Plasticell & GSK Sign Collaboration Agreement
Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem…
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates
AntriaBio, Inc. recently announced it is advancing the first development candidates from its oral plasma kallikrein inhibitor (PKI) portfolio. The two preclinical programs are AB402…
Ziopharm Oncology Announces First Patient Dosed in New Phase 1 Study
Ziopharm Oncology, Inc. recently announced that the first patient has been dosed in a new Phase 1 study of Ad-RTS-hIL-12 with veledimex for the treatment…
Ovid Therapeutics Announces Positive Preclinical Data
Ovid Therapeutics Inc. recently announced new positive preclinical data on OV101 that shows normalization of behavioral abnormalities that resemble those seen in people with Fragile…
